Start the conversation
Striking a Deal: Healthcare giant Pfizer Inc. (NYSE: PFE) announced a plan to manufacture cancer drugs with German rival Merck & Co. Inc. (NYSE: MRK). According to terms of the deal, Pfizer will pay an upfront fee to Merck worth $850 million. The deal could see Merck earn another $2 billion as the companies' efforts progress. This will likely end future speculation that Pfizer could purchase its international rival AstraZeneca Plc. (NYSE ADR: AZN).